Semaglutide, tirzepatide and retatrutide are the three incretin-class research peptides most often compared in metabolic studies. They are frequently discussed as if interchangeable. Mechanistically they are not, and the differences are the point of the comparison.

The Core Distinction: Receptor Count

The cleanest way to separate them is by how many receptors each engages.

Semaglutide is a single agonist at the GLP-1 receptor. It is a 31-amino-acid GLP-1 analog carrying an Aib substitution at position eight, which resists cleavage by the DPP-4 enzyme, plus a C18 fatty diacid chain promoting albumin binding.

Tirzepatide is a dual agonist at both the GIP and GLP-1 receptors — a 39-amino-acid peptide with a C20 fatty diacid modification. Its GIP arm is the addition relative to semaglutide.

Retatrutide is a triple agonist, adding glucagon receptor activity to the GIP and GLP-1 arms. It is discussed in more depth in the retatrutide guide.

Why Adding Receptors Changes the Profile

All three receptors are class B G protein-coupled receptors signaling largely through cyclic AMP, but they are expressed in different tissues, so each addition recruits a different downstream pattern.

The GLP-1 arm is the most characterized: glucose-dependent insulin secretion in pancreatic models and receptor signalling in central neuronal models. The GIP arm is more ambiguous in the literature, with reported effects in adipose and central tissue and some debate over whether agonism or antagonism produces the observed metabolic effects. The glucagon arm is the most distinct: it acts mainly on the liver, where glucagon receptor signalling regulates glucose output and lipid metabolism.

Notably, the glucagon arm is not simply additive — glucagon and GLP-1 signaling have partly opposing effects on glucose handling, so the balance of potencies matters more than the raw count of receptors engaged.

Structural and Pharmacokinetic Similarities

All three share a design strategy: modify the peptide backbone to resist enzymatic degradation, then attach a fatty-acid chain to promote albumin binding and extend circulating half-life. This is why all three are studied as long-acting compounds, and why comparative pharmacokinetic work often examines the acylation strategy independently of receptor pharmacology.

What Comparative Research Examines

Studies comparing the three typically measure relative binding affinity and functional potency at each receptor, cyclic AMP accumulation and beta-arrestin recruitment profiles, metabolic outcomes in rodent models, and whether multi-receptor engagement produces effects predictable from single-receptor data. A recurring question is whether added receptor arms produce genuinely additive effects or whether cross-talk alters the outcome.

Why Purity and Verification Matter

Reproducibility in peptide research depends on knowing exactly what is in the vial. Sequence-related impurities, truncated fragments and residual synthesis reagents can all influence experimental outcomes, and two preparations nominally of the same compound can behave differently if purity differs. Independent HPLC and mass spectrometry testing establishes both identity and purity, which is why third-party verification is standard practice for research-grade material. All compounds referenced here are supplied as lyophilized powder at 99%+ purity with independent verification.

Summary

The three compounds represent a progression in receptor coverage: semaglutide at GLP-1, tirzepatide at GIP and GLP-1, retatrutide adding glucagon. Because the receptors sit in different tissues and can act in partly opposing directions, the balance of potencies determines the profile rather than receptor count alone. All are intended strictly for laboratory research.

Related Research Peptides

Semaglutide 10mg · 20mg · Tirzepatide 10mg · 20mg · 30mg · 40mg · Retatrutide 10mg · Cagrilintide 5mg

For laboratory and research use only. Not for human or veterinary use, and not for diagnostic or therapeutic purposes.

Research material: Retatrutide in every vial size (5mg–60mg) · Tirzepatide in every vial size (5mg–100mg) · Semaglutide in every vial size (10mg–30mg)